By Nina Kienle

Schott Pharma, a German glass manufacturer specializing in the pharmaceutical industry, announced that it achieved its targets for the full year, thanks to the increasing demand for obesity treatments. In the fourth quarter, the company's revenue reached €229 million ($248.4 million), surpassing the previous year's figure of €203 million. The significant revenue growth was mainly driven by Schott Pharma's drug-delivery systems segment.

As part of its expansion efforts, Schott Pharma, listed on the Frankfurt Stock Exchange since September, is set to launch new products aimed at storing and delivering GLP-1 drugs used in the treatment of obesity.

The company reported a 7% increase in earnings before interest, taxes, depreciation, and amortization (EBITDA), which rose to €52 million. However, the EBITDA margin declined from 23.8% to 22.6%.

In addition to the successful fourth quarter, Schott Pharma's revenue for the full year rose by 9% to €899 million. The EBITDA also demonstrated growth, increasing by 9% to €239 million, while the margin slightly decreased from 26.8% to 26.6%.

Looking ahead to 2024, Schott Pharma anticipates organic revenue growth in the range of 9% to 11%. They also expect the EBITDA margin to remain stable compared to the 2023 level, reaffirming their positive mid-term outlook.

Apple's Response to New E-Commerce Regulations

Bristol Myers Squibb's Abecma Gene Therapy Receives Recommendation for Earlier Use in Europe

Leave A Reply

Your email address will not be published. Required fields are marked *